Trials / Unknown
UnknownNCT01021800
Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Blood Transfusion Centre of Slovenia · Other Government
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Interventional study of modulation of immune response in patients with pancreatic tubular adenocarcinoma after resection and gemcitabine treatment. When included, patients are pre-treated with moderate doses of cyclophosphamide. Then infusions of allogeneic mononuclear cells are given.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MIS | Cell infusion |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2011-12-01
- Completion
- 2012-12-01
- First posted
- 2009-11-30
- Last updated
- 2010-01-13
Locations
1 site across 1 country: Slovenia
Source: ClinicalTrials.gov record NCT01021800. Inclusion in this directory is not an endorsement.